The Global Alzheimer’s Initiative Now Act authorizes U.S. participation in the Davos Alzheimer's Collaborative to accelerate global efforts in preventing, diagnosing, and treating Alzheimer's and dementia, contingent upon securing matching international funds.
Ami Bera
Representative
CA-6
The Global Alzheimer’s Initiative Now Act establishes the U.S. policy to lead international efforts against the rapidly growing global crisis of Alzheimer's and dementia. This bill specifically authorizes U.S. participation and financial contribution to the Davos Alzheimer's Collaborative (DAC) to speed up research, prevention, and care worldwide. U.S. funding is contingent upon matching contributions from other sources, ensuring shared financial responsibility for global health initiatives. The President must also regularly report to Congress on U.S. involvement and the overall progress of DAC.
This new piece of legislation, the Global Alzheimer’s Initiative Now Act, is essentially the U.S. government deciding to put its money where its mouth is regarding the global fight against Alzheimer’s and dementia. The bill starts by laying out some pretty stark facts: globally, nearly 60 million people currently have these conditions, and that number is projected to hit 150 million by 2050. That’s more than cancer and HIV combined, and it’s expected to cost the global economy over $1.3 trillion annually, with costs doubling every decade. The policy established in this bill is straightforward: the U.S. will take a leadership role in international collaboration, focusing especially on low- and middle-income countries where cases are rising fastest.
If you’re juggling rising costs, this bill explains why this matters to your wallet, even if the disease hasn't hit your family yet. The bill notes that by 2050, the ratio of working-age people supporting older people is projected to more than double in most countries. This demographic shift puts immense pressure on social systems, healthcare, and national budgets—costs that inevitably filter down to taxpayers and employers. This bill is an attempt to get ahead of that curve by speeding up research and treatment globally, which theoretically lowers the long-term strain on everyone. It also highlights that women are disproportionately affected, both as patients and as caregivers, providing about 70% of all care hours.
The core of the Act is authorizing the U.S. to officially join and contribute funds to the Davos Alzheimer’s Collaborative (DAC). This is a group dedicated to accelerating global research, prevention, and care. Think of it as the U.S. buying a seat at the table where international solutions are being hammered out. The President gets to pick an experienced public health and development expert to represent the U.S. on DAC’s Advisory Council and potentially its Board, ensuring our interests and expertise are included in the global strategy.
Here’s the part that shows the bill’s commitment to fiscal responsibility and leveraging foreign aid: the U.S. contribution to DAC is capped, and it’s not a blank check. Specifically, the bill states that U.S. funding can only be spent if DAC first secures funding from other, non-U.S. sources. Furthermore, between fiscal years 2026 and 2030, the total U.S. contribution cannot exceed 33% of all money DAC receives from all sources combined. This is a smart safeguard, ensuring that U.S. taxpayer dollars are matched by other countries and private donors, maximizing the impact of our spending. This means for every dollar the U.S. puts in, the rest of the world has to put in at least two, a solid way to share the financial burden of a global problem. The President must also report annually to Congress on how the money is being used and how DAC’s work aligns with U.S. global health strategies.